

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

1. (currently amended) A method for screening ~~compounds~~ a compound useful for the treatment of proliferative and differentiative disorders comprising contacting a test compound in vitro with ~~a cell or a cell extract expressing Cks1 and Skp2~~ a reaction mixture comprising Skp2, p27, Cdk2 and Cks1; and detecting a change in Skp2 binding activity or Skp2 ubiquitin ligase activity, such that if a change in the binding activity or ubiquitin ligase activity of Skp2 is detected, then a compound useful for the treatment of proliferative or differentiative disorders is identified.
2. (previously presented) The method of claim 1 wherein the change in Skp2-binding activity is detected by detecting a change in the binding of Skp2 with either p27 or Cks1.
3. (previously presented) The method of Claim 1 wherein the change in the Skp2 ubiquitin ligase activity is detected by detecting a change in the ubiquitination or degradation of a ~~Skp2 specific substrate p27 or Cks1~~.
4. (canceled)
5. (canceled)
6. (canceled)
7. A method for screening a compound ~~compounds~~ useful for the treatment of proliferative and differentiative disorders comprising:
 - (a) ~~contacting adding~~ a test compound ~~to a~~ with a reaction mixture containing Skp2, Cks1, and a and one or both of: (i) a polypeptide corresponding to comprising the carboxy terminus of the human p27 chain having the sequence NAGSVEWTPKKPGLRRRQT (SEQ. ID. NO: 91) with or without a phosphothreonine at position 8 and (ii) ~~Cks1~~; and

(b) detecting a change in the interaction of Skp2 with Cks1 or the polypeptide, such that if a change in the interaction of Skp2 with Cks1 or the polypeptide is detected, then a compound useful for the treatment of proliferative and differentiative disorders is identified.

8. (previously presented) The method of Claim 7 wherein the change in the interaction of Skp2 with Cks1 or the polypeptide is detected by detecting a change in the binding of Skp2 to either the polypeptide or Cks1.

9. (previously presented) The method of Claim 7 wherein the change in the interaction of Skp2 with Cks1 or the polypeptide is detected by detecting a change in the ubiquitination or degradation of the polypeptide.

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (new) The method of claim 1 or 7 wherein said Cks1 is purified from an *in vitro* translation reaction or recombinant expression system.

23. (new) The method of claim 2 or 8 wherein the change in binding of Skp2 to Cks1 is detected by detecting an increase in the binding of Skp2 to Cks1.

24. (new) The method of claim 2 or 8 wherein the change in binding of Skp2 to Cks1 is detected by detecting a decrease in the binding of Skp2 to Cks1.

25. (new) The method of claim 2 wherein the change in binding of Skp2 and p27 is detected by detecting an increase in the binding of Skp2 to p27.

26. (new) The method of claim 2 wherein the change in binding of Skp2 and p27 is detected by detecting a decrease in the binding of Skp2 to p27.